Results 191 to 200 of about 13,432,161 (307)

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

open access: yesMolecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

open access: yesMolecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy